Illumina, Inc. (NASDAQ: ILMN) and MyOme, a leading genomics innovation and risk modeling company, today announced a collaboration and investment by Illumina into MyOme.
Van Andel Institute and Cure Parkinson’s have renewed a funding agreement to support the International Linked Clinical Trials Program, the world’s largest drug repurposing clinical trial initiative for Parkinson’s disease.
A new surgical device developed through University of Utah research is saving animals’ lives by helping them heal from serious, hard-to-treat bone infections—and providing a proof of concept for potential use in people.
A new Mayo Clinic study published in the New England Journal of Medicine has uncovered that an off-the-shelf, dual-antibody therapy can generate deep and durable responses in extramedullary multiple myeloma — one of the most aggressive and treatment-resistant forms of the disease.
A reporter's PressPass is required to access this story until the embargo expires on 11-Dec-2025 6:30 PM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
A clinical trial led by the UNC School of Medicine weighs medications versus ‘wait and see’ approach for treatment of patent ductus arteriosus, a common heart defect in extremely pre-term infants.
Depression has been traditionally treated globally as a disorder of brain chemistry. But what if the immune system is pulling more strings than we ever realized?
The finding points to a potential new treatment option for the most common subtype of breast cancer, which accounts for roughly 70% of all cases and is most often diagnosed at Stage 1, 2 or 3.
Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced results from the first independent validation of AidaBreastTM, a novel multi-omic biosignature developed to predict a woman's 10-year risk of locoregional recurrence (LRR) and her individualized benefit from adjuvant radiation therapy (RT) following breast-conserving surgery.
Growing up in Rio de Janeiro, Brazil, Daniel Chamié, MD, PhD, assistant professor of medicine (cardiovascular medicine), was immersed early in the world of interventional cardiology thanks to his father, a renowned interventional cardiologist in the structural and congenital heart diseases.
Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that they will present their Phase 1/2 study results of spevatamig (PT886) in combination with chemotherapy in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium held on Jan 8-10, 2026 in San Francisco, CA.
The December issue of the Journal of Cardiac Failure (JCF), now available, offers a robust lineup of original research, expert consensus, and clinical insights that explore heart failure (HF) through a multidisciplinary, inclusive, and globally engaged lens.
Novastra Therapeutics ("Novastra"), a Boston-founded, clinical-stage biotechnology company developing next-generation immune reprogramming therapies for cancer, today announced that its lead program, OAP-1 from its OmniAntigenTM XIRT platform, has entered a Phase 1b clinical study in patients with advanced solid tumors.
Novastra Therapeutics today announced early clinical results showing that its experimental cancer therapy, OAP-1, was safe and activated the immune system in patients with advanced solid tumors who had exhausted standard treatment options.
More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia were able to maintain safe platelet counts without serious bleeding episodes for at least one year.
CLEVELAND—Scientists working to enhance brain-computer interface (BCI) technology—which allows people to control devices with their thoughts—have found they can improve the performance of electrodes implanted in the brain by targeted delivery of anti-inflammatory drugs.
Antimicrobial peptides (AMPs) exhibit broad-spectrum antimicrobial activity, low propensity to induce bacterial resistance, and multifunctional properties including immunomodulation and tissue regeneration promotion.
Chief of Leukemia at Roswell Park to present studies on crenolanib and ziftomenib at the American Society of Hematology annual meeting.
A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same leukemia-causing gene mutation can have dramatically different outcomes: it depends on when in development the mutation first occurs.
EMBARGOED: A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma. Findings to be presented at ASH Dec. 8, 2025.